Efficacy and safety of interferon alpha-2b versus pegylated interferon alpha-2a monotherapy in children with chronic hepatitis B: a real-life cohort study from Shanghai, China

Hu, Yao; Ye, Yingzi; Ye, Li-Jing; Wang, Xiaohong; Yu, Hui

doi:10.1007/s12519-019-00303-w

Cited by 13 publications

(12 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, limited data showed that the antiviral monotherapy of using 48‐week IFN α‐2b (n = 18) or 48‐week Peg‐IFN‐α‐2a (n = 18) was well tolerated, and the rates of HBsAg clearance at 48 weeks post‐treatment were higher in IFN α‐2b group than Peg‐IFN‐α‐2a group (22.2% vs. 11.1%) (Table 1). However, the difference in benefits between IFN‐α and Peg‐IFN‐α‐2a antiviral therapy should be further evaluated in RCTs by enlarging the sample size 21 . Additionally, some studies reported that the combination of initial nucleoside/nucleotide analogs (NAs) and IFN‐α, and initial NAs and add‐on Peg‐IFN‐α‐2a therapy were safe and beneficial in children with CHB 11,22 (Table 1).…”

Section: Discussionmentioning

confidence: 99%

Long‐term benefits of interferon‐α therapy in children with HBeAg‐positive immune‐active chronic hepatitis B

Wang

Zhao

Liu

et al. 2021

Journal of Viral Hepatitis

View full text Add to dashboard Cite

The long‐term benefits of interferon‐α (IFN‐α) treatment in children with chronic hepatitis B (CHB) remain unclear. We conducted a retrospective and real‐world study to evaluate the safety and long‐term clearance rates of hepatitis B e antigen (HBeAg) and hepatitis B surface antigen (HBsAg) in CHB children who received IFN‐α monotherapy for 72 weeks and were with 13‐year follow‐up visit. Participants treated with IFN‐α (n = 316) were more likely to become HBeAg negatve (39.87% vs. 27.37%; p < .05) and HBsAg negative (11.08% vs. 3.16%; p < .05) by the end of the treatment period than untreated participants (n = 95). Treated participants also had higher cumulative rates of HBeAg loss (74.13% vs. 59.27%; p < .05) and HBsAg loss (46.95 vs. 33.11%; p < 0.05) than untreated participants in parallel by the end of 13‐year follow‐up. In particular, the cumulative rate of HBsAg loss was higher in treated children aged 1–7 years than in those aged 8–17 years (71.40% vs. 39.0%; p < .01). Children who were HBeAg‐negative at the end of IFN‐α treatment or who had serum alanine aminotransferase levels of ≥80 IU/L at baseline were likely to have higher cumulative HBsAg loss rates. Accordingly, HBeAg loss at 72 weeks was positively associated with the cumulative HBsAg loss rate in untreated children. There were no serious adverse events of IFN‐α therapy for the treated patients throughout the study period. Overall, IFN‐α therapy was effective in obtaining higher long‐term cumulative rates of HBeAg and HBsAg loss in children with HBeAg‐positive immune‐active CHB, especially among those aged 1–7 years.

show abstract

Section: Discussionmentioning

confidence: 99%

Long‐term benefits of interferon‐α therapy in children with HBeAg‐positive immune‐active chronic hepatitis B

Wang

Zhao

Liu

et al. 2021

Journal of Viral Hepatitis

View full text Add to dashboard Cite

show abstract

“…IFN-α is presently the first choice of antiviral therapy for children with CHB older than one year, whereas PEG-IFN-α-2a is the recommended treatment for children with CHB older than three years. The results showed that antiviral monotherapy with IFNα-2B or PEG-IFNα-2a was well tolerated and effective in CHB children compared with adults with higher HBeAg seroconversion rates and HBsAg clearance rates ( 69 ). Many studies have shown that standard IFN-α has a specific role in anti-HBV infection; however, pure IFN-α is not commonly given as a therapy in clinical trials ( 70 ).…”

Section: Ifns and Peg-ifnsmentioning

confidence: 99%

Interferon and interferon-stimulated genes in HBV treatment

Sun

Yang

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Human hepatitis B virus (HBV) is a small enveloped DNA virus with a complex life cycle. It is the causative agent of acute and chronic hepatitis. HBV can resist immune system responses and often causes persistent chronic infections. HBV is the leading cause of liver cancer and cirrhosis. Interferons (IFNs) are cytokines with antiviral, immunomodulatory, and antitumor properties. IFNs are glycoproteins with a strong antiviral activity that plays an important role in adaptive and innate immune responses. They are classified into three categories (type I, II, and III) based on the structure of their cell-surface receptors. As an effective drug for controlling chronic viral infections, Type I IFNs are approved to be clinically used for the treatment of HBV infection. The therapeutic effect of interferon will be enhanced when combined with other drugs. IFNs play a biological function by inducing the expression of hundreds of IFN-stimulated genes (ISGs) in the host cells, which are responsible for the inhibiting of HBV replication, transcription, and other important processes. Animal models of HBV, such as chimpanzees, are also important tools for studying IFN treatment and ISG regulation. In the present review, we summarized the recent progress in IFN-HBV treatment and focused on its mechanism through the interaction between HBV and ISGs.

show abstract

“…Such diseases include respiratory infections and hepatitis. The use of, interferon alfa-2b allows in some cases to exclude the use of antibiotics and other antibacterial drugs, increases the effectiveness of antibacterial and antiviral therapy as part of complex therapy [1][2][3][4]. In addition, there is data on the effectiveness of interferon treatment of some types of cancer [5,6].…”

Section: Introductionmentioning

confidence: 99%

The Development and Study of the Toxicity of Suppositories With a Modified Substance of Interferon Alfa-2b

Анурова

E.O.²,

Shumkova³

et al. 2023

Int J App Pharm

View full text Add to dashboard Cite

Objective: To develop a stable composition with the substance of PEGylated interferon alfa-2b, to study technological and biopharmaceutical characteristics of the dosage form, and to conduct preclinical studies on the chronic toxicity and local irritating effect. Methods: Solid fats Witepsol® H15, Witepsol® W 35, Suppocire® BS2X, and Suppocire® BM brands were used as the suppository bases. Polysorbate 80 was used as an emulsifier. Citric acid, ascorbic acid, sodium tetraborate, lactic acid, ethylenediaminetetetraacetic acid, tocopherol acetate was also introduced into the experimental samples. Fourteen experimental samples were screened for biological and technological indicators. Preclinical studies were performed for the optimal composition on the indicators of chronic toxicity and local irritant effect. Results: The study examined the cytotoxic effects on the Vero cell line of selected suppository bases and excipients, namely, pH regulators and antioxidants. With excipients that did not have cytotoxicity we obtained suppository compositions with the following quality indicators: cytotoxicity, specific activity of interferon, time of complete deformation of suppositories and their melting temperature. A total of 14 compositions were studied, of which 5 were selected on the basis of the results for the study of stability. Only one composition turned out to be stable for the time studied. Conclusion: The most stable in terms of “specific activity” was sample 7, its composition: Witepsol® H15/W35 70/30, polysorbate-80 0.15%, ethylenediaminetetraacetic acid (EDTA) 0.15%, sodium tetraborate 0.15%, tocopherol acetate 3.0%. Preclinical studies, that showed the absence of chronic toxicity and local irritant effect, were performed for this composition.

show abstract

Efficacy and safety of interferon alpha-2b versus pegylated interferon alpha-2a monotherapy in children with chronic hepatitis B: a real-life cohort study from Shanghai, China

Cited by 13 publications

References 23 publications

Long‐term benefits of interferon‐α therapy in children with HBeAg‐positive immune‐active chronic hepatitis B

Long‐term benefits of interferon‐α therapy in children with HBeAg‐positive immune‐active chronic hepatitis B

Interferon and interferon-stimulated genes in HBV treatment

The Development and Study of the Toxicity of Suppositories With a Modified Substance of Interferon Alfa-2b

Contact Info

Product

Resources

About